T

op of the morning to you, and a fine one, it is. A sunny sky and a cool breeze are enveloping the cozy Pharmalot campus, where the usual routine was briefly altered when the short person required extra help reaching the local schoolhouse. Now, though, the rhythm has returned as we forage for items of interest. Speaking of which, here are some tidbits to help you along during what is likely to be a busy day, yes? So grab your cup of stimulation and dig in. Hope all goes well and do keep in touch. We enjoy hearing and reading secrets …

Shire (SHPG) filed an antitrust lawsuit accusing Allergan (AGN) of using contracts with Medicare Part D plans to block access to its Xiidra eye drops, which compete with Allergan’s Restasis drops. “We do not see how Allergan‘s discounting and rebating is different from the normal course of action in the pharmaceutical industry,” Wells Fargo analyst David Maris writes. “These allegations are very common,” Herbert Hovenkamp, an antitrust expert at the University of Pennsylvania, tells The Wall Street Journal. “They are not easy to prove.”

This is a STAT Plus article and you can unlock it by subscribing to STAT Plus today. It's easy! Your first 30 days are free and if you don't enjoy your subscription you can cancel any time.
Already a subscriber? Log in here.

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Biotech newsletter — The Readout

Your daily guide to what’s new in biotech.

X